Market Cap | 75.11M | P/E | - | EPS this Y | 1.40% | Ern Qtrly Grth | - |
Income | -16.91M | Forward P/E | -4.03 | EPS next Y | 25.40% | 50D Avg Chg | 7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -57.00% |
Recommedations | 2.50 | Quick Ratio | 6.45 | Shares Outstanding | 26.56M | 52W Low Chg | 159.00% |
Insider Own | 29.25% | ROA | -69.75% | Shares Float | 19.27M | Beta | -0.99 |
Inst Own | 8.49% | ROE | -113.62% | Shares Shorted/Prior | 82.09K/179.67K | Price | 2.90 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 508,666 | Target Price | 5.00 |
Oper. Margin | - | Earnings Date | Aug 14 | Volume | 42,809 | Change | -4.92% |
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Benchmark | Speculative Buy | May 13, 24 |
Benchmark | Speculative Buy | Mar 25, 24 |
Benchmark | Speculative Buy | Nov 16, 23 |
Benchmark | Speculative Buy | Aug 24, 23 |
Alliance Global Partners | Buy | May 19, 23 |
Benchmark | Speculative Buy | May 19, 23 |
Benchmark | Speculative Buy | Mar 21, 23 |
Alliance Global Partners | Buy | Dec 2, 22 |
Benchmark | Speculative Buy | Dec 20, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
de Urioste George | Director Director | Sep 29 | Sell | 2.06 | 5,500 | 11,330 | 36,129 | 10/03/23 |
de Urioste George | Director Director | Sep 27 | Sell | 2.08 | 9,834 | 20,455 | 41,629 | 09/29/23 |
de Urioste George | Director Director | Sep 22 | Sell | 2.15 | 7,393 | 15,895 | 51,463 | 09/27/23 |
de Urioste George | Director Director | Sep 20 | Sell | 2.44 | 983 | 2,399 | 58,856 | 09/22/23 |
de Urioste George | Director Director | Sep 15 | Sell | 2.45 | 9,269 | 22,709 | 59,839 | 09/19/23 |
de Urioste George | Director Director | Sep 13 | Sell | 2.01 | 10,000 | 20,100 | 69,108 | 09/15/23 |
Brounstein Richard | Chief Financial Offi.. Chief Financial Officer | Nov 02 | Option | 0.0003 | 759 | 111,164 | 11/02/22 | |
Brounstein Richard | Chief Financial Offi.. Chief Financial Officer | Sep 02 | Option | 0.0003 | 757 | 109,645 | 09/02/22 | |
Brounstein Richard | Chief Financial Offi.. Chief Financial Officer | Aug 02 | Option | 0.0003 | 757 | 108,888 | 08/02/22 | |
Brounstein Richard | Chief Financial Offi.. Chief Financial Officer | Jul 05 | Option | 0.0003 | 757 | 108,131 | 07/06/22 | |
Brounstein Richard | Chief Financial Offi.. Chief Financial Officer | May 02 | Option | 0.0003 | 757 | 106,617 | 05/02/22 | |
BROUNSTEIN RICHARD D | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 11 | Option | 4.2 | 29,197 | 122,627 | 92,075 | 11/15/21 |
BROUNSTEIN RICHARD D | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 11 | Buy | 5.99 | 5,000 | 29,950 | 97,075 | 11/15/21 |
Ortigas-Wedekind Marga | Director Director | Nov 11 | Option | 4.2 | 7,824 | 32,861 | 7,824 | 11/15/21 |
Ortigas-Wedekind Marga | Director Director | Nov 11 | Buy | 5.99 | 9,000 | 53,910 | 16,824 | 11/15/21 |
Elfrink Willhem | Director Director | Nov 11 | Option | 4.2 | 332,407 | 1,396,109 | 437,861 | 11/15/21 |